Adial Pharmaceuticals to Highlight Breakthroughs in Addiction Treatment at H.C. Wainwright Global Investment Co...

GLEN ALLEN, Va., Sept. 04, 2024' Adial Pharmaceuticals, Inc. (NASDAQ: ADIL), a clinical-stage biopharmaceutical company dedicated to developing innovative therapies for the treatment and prevention of addiction and related disorders, has announced its participation in the H.C. Wainwright 26th Annual Global Investment Conference. The event is scheduled to take place from September 9 to 11, 2024, at the Lotte New York Palace Hotel in New York City.

Cary Claiborne, the CEO of Adial Pharmaceuticals, will represent the company at this prestigious conference. Claiborne will discuss the company?s recent milestones, ongoing clinical trials, and future plans. This presentation is a critical opportunity for Adial to connect with potential investors and pharmaceutical partners, especially as it advances its promising portfolio of addiction treatments.

Recent Milestones and Achievements

Publication Supporting Efficacy of AD04

Adial Pharmaceuticals recently achieved significant recognition in the medical community with the publication of research findings in a leading peer-reviewed journal. The study highlights the potential efficacy of its drug candidate AD04 as a precision medicine for the treatment of Alcohol Use Disorder (AUD).

The results demonstrated that AD04 significantly reduced heavy drinking days among individuals diagnosed with AUD who also possess a specific genetic profile. This genetic profile was identified using a companion diagnostic test (CDx), underscoring the importance of personalized medicine in treating addiction. The conclusive evidence supporting AD04 as an effective therapy for a targeted patient population marks a substantial advancement in the treatment landscape for AUD.

Initiation of Pharmacokinetics Study for AD04

Further progressing its clinical programs, Adial Pharmaceuticals has initiated a pivotal pharmacokinetics study for AD04. The first patient has already been dosed, marking an important milestone in the drug's development cycle. The primary of this study is to optimize design elements required for the impending U.S. Pivotal Phase 3 studies.

These preparations are crucial as the company gears up to present compelling data to both regulatory authorities and potential pharmaceutical partners. The pharmacokinetics study will refine the dosing protocol and ensure that AD04 can deliver consistent, effective results in larger patient populations.

Strategic Implications

The achievements of Adial Pharmaceuticals highlight the company's methodical approach to drug development. The combination of solid clinical data, strategic pharmacokinetics studies, and targeted therapeutic development underscores Adial's commitment to bringing innovative solutions to market. Participation in high-profile events like the H.C. Wainwright Annual Global Investment Conference enhances the company's visibility and strengthens its position within the biopharmaceutical industry.

Claiborne?s presentation will likely cover these significant milestones and emphasize the company's focused strategy on precision medicine. His discourse will be an excellent opportunity to showcase how AD04 and other pipeline projects align with the emerging trends in addiction treatment, drawing interest and potential collaborations from a global audience of investors and industry leaders.

Conclusion

Adial Pharmaceuticals is at a promising juncture, making significant strides towards bringing effective treatments for addiction to market. The company?s ongoing commitment to innovation and excellence in clinical research positions it favorably within the biopharmaceutical sector. With important endorsement from peer-reviewed publications and the initiation of critical pharmacokinetics studies, Adial is moving confidently towards its goal of addressing the unmet needs in the treatment of Alcohol Use Disorder.

More 's News

Adial Pharmaceuticals Inc Adial Pharmaceuticals Begins Patient Dosing in Second Cohort of Pharmacokinetics Study for AD04, an Innovative Treatm... July 23, 2024

Adial Pharmaceuticals Inc Adial Pharmaceuticals Announces Publication in Leading Peer-Reviewed Journal Supporting the Potential Efficacy of AD0... June 20, 2024

Adial Pharmaceuticals Inc Adial Pharmaceuticals Achieves Key Milestone in AD04 Pharmacokinetics Study for Alcohol Use Disorder Treatment June 5, 2024

More Clinical Study News

Clinical Study Cingulate Bolsters ADHD Treatment Pipeline $10 Million Secured for Final Studies of CTx-1301, Promising Revolution ... September 12, 2024

Clinical Study Evolving Treatment NKGen Biotechs Promising Advances in Alzheimers and Solid Tumor Therapies September 12, 2024

Clinical Study Vera Therapeutics Completes Ahead-of-Schedule Enrollment in Phase 3 ORIGIN 3 Trial of Atacicept for IgA Nephropathy September 12, 2024

Previous News

The Investment Center, Inc Enhances Service Offerings as LPL Financial Prepares for Strategic Acquisition

Collegium Pharmaceuticals Expands Neurology Footprint with the Launch of Jornay PM,

Vertex Inc. Acquires ecosio, Expanding Its Indirect Tax Solutions to EDI and E-Invoicing

GoHealth Acquiring e-TeleQuote: Strengthening Position as Leading Medicare Insurance Marketplace

Business First Bancshares, Inc. Secures Regulatory Approval for Oakwood Merger: A Positive Step Towards Growth

BrightSpring Health Services Expands Hospice Footprint with Acquisition of Haven Hospice in Florida

Tilray's Bold Step: A Craft Beer Revival with Molson Coors Acquisition,

First National Corporation and Touchstone Bankshares, Inc. Secure Shareholder Approval for Merger, Signaling New Era in Banking Services

Weatherford Strengthens Digital Offering with Acquisition of Datagration Solutions,

SPAR Group Inc Enters into Definitive Agreement to be Acquired by Highwire Capital